A resident of the Technopolis Moscow special economic zone has increased its production output by 30 percent

Over the eight months of 2026, the Moscow SEZ resident, the biotechnology company Artsellens, supplied more than a million packages of medications for the treatment of oncological, autoimmune, and cardiovascular diseases, as well as diabetes. The company is developing with the support of the Moscow Fund for Industry and Entrepreneurship Support (MFII). This was reported by Maxim Liksutov, Deputy Mayor of Moscow for Transport and Industry.

“On the instructions of Moscow Mayor Sergei Sobyanin, the city is providing comprehensive support to key industrial sectors.” Thanks to this, the company is improving and expanding its own technological base. For example, one of the capital’s pharmaceutical manufacturers was able to increase its output by 30 percent this year thanks to increased capacity, and between January and August, it shipped over a million packages of medicines. Assistance from the Moscow Fund for the Support of Industry and Entrepreneurship, as well as investment lending programs, plays a significant role. They help reduce the financial burden and direct the freed‑up funds to production development,” said Maxim Liksutov.

In 2026, the company also launched an experimental‑industrial unit for the biological synthesis of monoclonal antibodies and obtained a license for their production.

Along with the development of infrastructure, the plant is expanding its research program. Since the beginning of the year, Artsellens has launched cooperation with more than ten new research groups from Russian universities and research institutes. One of the areas of collaboration is the development of solutions based on RNA technologies.

“In 2026, thanks to the launch of new production capacities, we increased our output. In biotechnology, the development of production requires significant long—term investments, so support tools can reduce the financial burden on the project and direct more resources directly to research and development," said Ilya Bardin-Denisov, CEO of Artsellens.

Earlier, Moscow Mayor Sergei Sobyanin spoke about new industrial sites in Moscow. One of them is the production of Artsellens. The company has completed the construction of a new high-tech pharmaceutical plant that will produce innovative biotechnological drugs for the treatment of cancer, autoimmune and other diseases.

The investment lending program of the Moscow Institute of Finance and Law provides for compensation of the interest rate in the amount of 50 percent of the key rate of the Central Bank of the Russian Federation. The maximum support period is five years, and the maximum amount subject to compensation is five billion rubles.

Moscow is actively developing its investment climate and industrial potential. Thanks to city‑level solutions, labour productivity and production efficiency are growing. Such measures contribute to the implementation of the national project “Efficient and Competitive Economy”.